|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.12 HKD | -2.26% |
|
+2.02% | -6.84% |
| 03-11 | Abbisko Drug Receives Rare Pediatric Designation in U.S. | MT |
| 03-11 | Abbisko Cayman says US FDA grants rare pediatric disease designation for FGFR2/3 inhibitor ABSK061 | RE |
Company Valuation: Abbisko Cayman Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,209 | 1,993 | 2,146 | 2,703 | 7,179 | 7,179 | - |
| Change | - | -61.74% | 7.72% | 25.92% | 165.62% | 0% | - |
| Enterprise Value (EV) 1 | 2,717 | -220.6 | 175 | 767.9 | 5,317 | 5,874 | 5,830 |
| Change | - | -108.12% | 179.31% | 338.89% | 592.49% | 10.48% | -0.75% |
| P/E ratio | -0.96x | -3.55x | -4.94x | 108x | 130x | -158x | -95.2x |
| PBR | 2.05x | 0.75x | 1.08x | 1.4x | 3.37x | 3.77x | 3x |
| PEG | - | 0x | 0.3x | -1x | 1x | 1x | -1.5x |
| Capitalization / Revenue | 230x | - | 113x | 5.36x | 12.8x | 30.6x | 12.2x |
| EV / Revenue | 120x | - | 9.18x | 1.52x | 8.32x | 25x | 9.87x |
| EV / EBITDA | -8.59x | 0.46x | -0.36x | 388x | 50.1x | -17.1x | -82.3x |
| EV / EBIT | -8.28x | 0.44x | -0.34x | -35.6x | 53.8x | -16.8x | -82.7x |
| EV / FCF | -15.2x | 0.61x | -0.39x | -37.8x | -506x | 63.5x | 45.5x |
| FCF Yield | -6.58% | 165% | -260% | -2.65% | -0.2% | 1.57% | 2.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -7.71 | -0.8 | -0.67 | 0.04 | 0.09 | -0.0678 | -0.1122 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 22.68 | - | 19.06 | 504 | 612.1 | 235 | 590.4 |
| EBITDA 1 | -316.2 | -481.4 | -492.7 | 1.978 | 106.2 | -343.7 | -70.86 |
| EBIT 1 | -328.2 | -497.2 | -511.1 | -21.59 | 27.9 | -350.1 | -70.49 |
| Net income 1 | -1,810 | -495.6 | -431.6 | 28.3 | 55.25 | -19.19 | -30.83 |
| Net Debt 1 | -2,492 | -2,213 | -1,971 | -1,935 | -1,862 | -1,305 | -1,349 |
| Reference price 2 | 7.41 | 2.84 | 3.31 | 4.32 | 10.68 | 10.68 | 10.68 |
| Nbr of stocks (in thousands) | 702,578 | 701,774 | 647,858 | 625,264 | 672,361 | 672,361 | - |
| Announcement Date | 18/03/22 | 15/03/23 | 12/03/24 | 03/03/25 | 02/03/26 | - | - |
1CNY in Million2CNY
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 43.54x | 8.32x | 50.07x | -.--% | 1.04B | |
| 41.47x | 9.67x | 34.91x | 0.03% | 42.98B | |
| 15.59x | 5.55x | 12.22x | 1.92% | 39.24B | |
| -51.87x | 17.46x | -57.69x | -.--% | 30.07B | |
| -17.46x | 4.3x | -8.04x | -.--% | 21.88B | |
| 27.73x | 5.41x | 15.05x | -.--% | 18.25B | |
| 21.68x | 4.07x | 13.29x | -.--% | 16.03B | |
| -316.87x | 26.28x | 1446.95x | -.--% | 12.97B | |
| -14.42x | 6446.99x | -18.43x | -.--% | 12.5B | |
| -164.89x | 40.26x | -159.9x | -.--% | 11.76B | |
| Average | -41.55x | 656.83x | 132.84x | 0.19% | 20.67B | |
| Weighted average by Cap. | -23.60x | 400.66x | 83.51x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 2256 Stock
- Valuation Abbisko Cayman Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition